AI Agent Governance for Clinical Trial Site Monitoring
Governing AI agents in clinical trial site monitoring requires extending existing 21 CFR Part 11 and ICH E6(R2) controls to agent behavior specifically: a distinct agent identity separate from human credentials, least-privilege scoping to only the trial systems and data fields a task requires, runtime enforcement that blocks out-of-scope actions before they execute, and tool-call level audit logging sufficient to reconstruct agent behavior during a regulatory inspection. No current FDA, EMA, or ICH guidance addresses AI agents specifically, so organizations must interpret and apply existing computerized system validation and GCP oversight requirements to these tools until specific guidance is issued.
Core Governance Requirements
Four controls form the baseline for any AI agent granted access to clinical trial systems.
Agent Identity
Distinct, revocable credentials separate from human users.
Least Privilege
Scoped access to specific systems and data fields per task.
Runtime Enforcement
Blocking out-of-scope actions before execution, not just after.
Audit Logging
Tool-call level records that can be reconstructed for inspection.
Where Runtime Enforcement Fits
-
1
Runtime Policy Enforcement vs. Post-Hoc Logging
Runtime policy enforcement is architecturally distinct from post-hoc logging, and it addresses a gap that logging alone cannot close. Logs can confirm what an agent did after the fact, but they cannot prevent an out-of-scope action from occurring in the first place. Enforcement at the point of execution is what stops the action; logging only documents it.
Evaluation Questions Before Granting System Access
Before an AI agent is given credentials to any trial system, governance leaders should be able to answer the following questions with specificity.
- What specific trial systems and data fields will the agent be permitted to access, and how is that scope enforced at runtime rather than documented only in policy?
- How is the agent's identity distinguished from human user credentials in audit trails and access logs?
- What mechanism prevents the agent from executing an out-of-scope action before it occurs, rather than only detecting it afterward?
- How are agent-flagged findings routed for review and attribution to a qualified human decision-maker?
- What validation and change control documentation exists for the agent, consistent with computerized system validation already applied to other GCP systems?
Why This Use Case Carries Elevated Risk
Clinical trial site monitoring sits at the intersection of patient safety, data integrity, and regulatory oversight. When an AI agent is introduced into this workflow, it inherits access to protected health information, source documents, and systems that regulators expect to be tightly controlled. Any ambiguity in what the agent is permitted to do, or in who is accountable for its actions, creates risk that extends beyond a single trial to an organization's broader GCP compliance posture.
What Existing Regulation Already Requires
Neither 21 CFR Part 11 nor ICH E6(R2) was written with AI agents in mind, but both already impose obligations that apply directly to agent-based tools. Computerized system validation, audit trail integrity, and documented change control are established expectations for any system touching trial data. Governance leaders should treat an AI agent as a computerized system subject to these same expectations rather than waiting for agent-specific guidance to be issued.
The Attribution Problem Unique to Agents
Human monitors operate under individual credentials that make their actions attributable by default. Agents complicate this. If an agent operates under a shared service account or borrows a human user's credentials, it becomes difficult or impossible to reconstruct, during an inspection, whether a given action was taken by a person or by the agent acting on that person's behalf. A distinct, non-human identity for the agent is the mechanism that resolves this.
Logging After the Fact Is Not Sufficient
Comprehensive logging is necessary but not sufficient. Logging tells you what happened; it does not stop an out-of-scope action from happening. Runtime enforcement, meaning policy checks applied at the moment a tool call or system action is attempted, is what actually prevents an agent from reading a data field or invoking a system function outside its authorized scope. Organizations that rely solely on log review for oversight will only discover a scope violation after it has already occurred.
Implementation Sequence for Governance Leaders
A defensible rollout generally follows a consistent order: define the agent's task scope narrowly, assign it a distinct identity, enforce that scope at runtime, and log every tool call at a level of detail sufficient to reconstruct behavior later. Human review and attribution should be built into the workflow for any finding the agent surfaces, so that clinical judgment, not the agent, remains the basis for decisions affecting trial conduct or patient safety.
Where Trussed AI Fits in This Model
Trussed AI provides the identity, permission scoping, and runtime enforcement layer that this model depends on. Rather than relying on policy documentation alone or on logging as the primary control, Trussed AI enforces least-privilege access at the point an agent attempts an action, and it maintains tool-call level audit records that support the attribution and inspection readiness described above.
Evaluate Runtime Governance Before Deployment
Before granting an AI agent access to clinical trial systems, confirm its identity, permission scope, and runtime enforcement model meet the same attribution and audit standards already required of human monitoring activity.
Request a Demo